1. Home
  2. BMEA vs INVZ Comparison

BMEA vs INVZ Comparison

Compare BMEA & INVZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

N/A

Current Price

$1.73

Market Cap

115.2M

Sector

Health Care

ML Signal

N/A

Logo Innoviz Technologies Ltd. Ordinary shares

INVZ

Innoviz Technologies Ltd. Ordinary shares

HOLD

Current Price

$0.35

Market Cap

129.5M

ML Signal

HOLD

Company Overview

Basic Information
Metric
BMEA
INVZ
Founded
2017
2016
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Auto Parts:O.E.M.
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
115.2M
129.5M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
BMEA
INVZ
Price
$1.73
$0.35
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
3
Target Price
$9.83
$2.68
AVG Volume (30 Days)
1.4M
4.1M
Earning Date
05-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
69.19
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$29.61
Revenue Next Year
N/A
$53.57
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.87
$0.32
52 Week High
$2.99
$2.54

Technical Indicators

Market Signals
Indicator
BMEA
INVZ
Relative Strength Index (RSI) 75.92 37.15
Support Level $1.23 $0.35
Resistance Level $1.69 $0.47
Average True Range (ATR) 0.11 0.02
MACD 0.04 0.01
Stochastic Oscillator 72.03 45.18

Price Performance

Historical Comparison
BMEA
INVZ

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.

About INVZ Innoviz Technologies Ltd. Ordinary shares

Innoviz Technologies Ltd is a provider of LiDAR technology, serving as a Tier 1 supplier to the world's automotive manufacturers. Its LiDAR and perception software "see" further than a human driver and reduce the possibility of error, meeting the automotive industry's strictest expectations for performance and safety. Its sensors are designed to deliver exceptional range, resolution, and reliability, providing accurate 3D sensing in harsh weather conditions. Operating across the U.S., Europe, and Asia. Innoviz designs solutions for automotive OEMs, system integrators, municipalities, commercial enterprises, and others. InnovizSMART is an off-the-shelf solution for security, defense, and homeland security, intelligent traffic management, mobility, robotics, and aerial applications.

Share on Social Networks: